Along with a panel of experts, IMF Chief Medical Officer Dr. Joseph Mikhael will speak on advances in myeloma research from the 2024 ASH Conference.
At the upcoming International Myeloma Working Group (IMWG) Conference Series, “Making Sense of Treatment,” leading myeloma experts will discuss the latest drug therapy news from the December 2024 American Society of Hematology (ASH) Conference which will take place in San Diego, CA.
IMF Chief Medical Officer Joseph Mikhael, MD will moderate the discussion, with Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (IMF Nurse Leadership Board Member, Cleveland Clinic, Taussig Cancer Center), Nikhil Munshi, MD (Dana-Farber Cancer Institute), and S. Vincent Rajkumar, MD (IMF Chairperson of the Board, Mayo Clinic – Rochester) serving as panelists.
Dr. Mikhael will open the session by discussing the large number of myeloma abstracts from the ASH annual conference this year. He will then share highlights from the IMF IMWG Breakfast.
The panel and Dr. Mikhael will then focus on the following topics:
- Monoclonal gammopathy of undetermined significance (MGUS) and Smoldering Multiple Myeloma (SMM)
- Current Challenges in Multiple Myeloma
- Future Directions of Frontline Therapy
- Immune Therapies (CAR T-cell and Bispecifics) and Next Generation Approaches
- New Myeloma Drugs and Endpoints
